Private equity firm Blackstone Life Sciences has partnered with Swiss drugmaker Novartis to launch a company to develop a heart drug, according to The Wall Street Journal.
The new company, Anthos Therapeutics, will start by advancing a Novartis antibody that targets two clotting factors. The idea is to develop a drug that treats blood clots in acute and chronic situations to prevent a variety of cardiovascular disorders.
The company is backed by a $250 million investment from Blackstone, which will control the company. Novartis will have a minority stake.
Date: March 4, 2019